Please login to the form below

Not currently logged in
Email:
Password:

AZ's Brilinta approved in Canada

Health Canada has approved AstraZeneca's Brilinta to prevent blood clots in patients with acute coronary syndrome

Health Canada has approved AstraZeneca's (AZ) Brilinta (ticagrelor) for the secondary prevention of atherothrombotic events, such as blood clots, in patients with acute coronary syndrome.

The approval comes seven months after the drug was denied approval by the US Food and Drug Administration (FDA), with studies demonstrating that patients were more likely to experience heart problems with Brilinta than rival drug Plavix (clopidogrel), despite AZ's treatment having greater efficacy.

The FDA did not request additional studies, but did ask for additional analyses of the data from the company's PLATO trial. The drug remains in review in the US, as well as Russia, India and China.

Including Canada, Brilinta has now been approved in 33 countries, including in the European Union under the name Brilique.

1st June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics